J. Slingerland

1.1k total citations
17 papers, 924 citations indexed

About

J. Slingerland is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J. Slingerland has authored 17 papers receiving a total of 924 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in J. Slingerland's work include Cancer Treatment and Pharmacology (5 papers), Cancer-related Molecular Pathways (5 papers) and Advanced Breast Cancer Therapies (4 papers). J. Slingerland is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Cancer-related Molecular Pathways (5 papers) and Advanced Breast Cancer Therapies (4 papers). J. Slingerland collaborates with scholars based in Canada, United States and Singapore. J. Slingerland's co-authors include Samuel Benchimol, MD Minden, John R. Jenkins, Izabella Morava-Protzner, John Tsihlias, Nandita Bhattacharya, George Deboer, I Zbieranowski, Michele Pagano and Teresa Petrocelli and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and Blood.

In The Last Decade

J. Slingerland

16 papers receiving 897 citations

Peers

Countries citing papers authored by J. Slingerland

Since Specialization

Citations

This map shows the geographic impact of J. Slingerland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Slingerland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Slingerland more than expected).

Fields of papers citing papers by J. Slingerland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Slingerland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Slingerland. The network helps show where J. Slingerland may publish in the future.

Co-authorship network of co-authors of J. Slingerland

This figure shows the co-authorship network connecting the top 25 collaborators of J. Slingerland. A scholar is included among the top collaborators of J. Slingerland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Slingerland. J. Slingerland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Abstract P2-01-10: Circulating CAF/CTC complexes and breast cancer metastasis 2018 ·Cancer Research ·Paula G. Miller, (unknown), (unknown), Toni M. Yeasky, Manuel Picon‐Ruiz, Cynthia Morata‐Tarifa, (unknown), J. Slingerland, (unknown), Dorraya El‐Ashry	2
2	Generation of a Plasma Microrna (Mirna) Signature Predicting Response to Metronomic Chemotherapy (Mc) for Advanced Breast Cancer (Abc) 2014 ·Annals of Oncology ·Urban Emmenegger, Berta Sousa, (unknown), Ariel Ka-Man Chow, (unknown), Susan Dent, (unknown), (unknown), (unknown), J. Slingerland, Andrew Eisen, John M.L. Ebos, KW Chan, Sharon L. Gardner, K. I. Pritchard	1
3	Promotion of cytoplasmic mislocalization of p27 by Helicobacter pylori in gastric cancer 2011 ·Oncogene ·Si Wen, Young So, Kamaljeet Singh, J. Slingerland, Murray B. Resnick, Siyuan Zhang, Victoria Ruiz, Steven F. Moss	27
4	Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer 2011 ·Breast Cancer Research and Treatment ·Alberto J. Montero, C. Marcela Díaz‐Montero, Yehuda E. Deutsch, Judith Hurley, Leonidas G. Koniaris, Tihana Rumboldt, Saba Yasir, (unknown), (unknown), Eli Avisar, J. Slingerland, (unknown), Catherine F. Welsh, (unknown), Pearl H. Seo, Mark D. Pegram, Stefan Glück	90
5	Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer 2010 ·Endocrine Related Cancer ·Adam Rosenblatt, (unknown), Leah Lyons, Yong Xie, (unknown), Laurent Désiré, J. Slingerland, Kerry L. Burnstein	51
6	Abstract P2-19-03: Src Kinase Inhibition with AZD0530 Plus Anastrozole in Postmenopausal Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC) 2010 ·Cancer Research ·(unknown), (unknown), Christopher F. Higgins, (unknown), Eli Avisar, Melissa K. Stuart, J. Slingerland	2
7	Phase IB pharmacokinetic (PK) study of Src kinase inhibitor AZD0530 plus anastrozole in postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC). 2010 ·Journal of Clinical Oncology ·Mark D. Pegram, (unknown), Christopher F. Higgins, (unknown), Melissa K. Stuart, J. Slingerland	3
8	470 Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer 2010 ·European Journal of Cancer Supplements ·Stefan Glück, (unknown), (unknown), Aurelio Castrellon, (unknown), Isildinha M. Reis, Susan D. Richman, (unknown), J. Slingerland, Catherine F. Welsh	1
9	Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC) 2008 ·Journal of Clinical Oncology ·Stefan Glück, (unknown), Isildinha M. Reis, (unknown), (unknown), (unknown), (unknown), Pearl H. Seo, (unknown), J. Slingerland, Catherine F. Welsh	5
10	Regulation of the Cdk inhibitor p27 and its deregulation in cancer 2000 ·Journal of Cellular Physiology ·J. Slingerland, Michele Pagano	29
11	Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. 1998 ·PubMed ·John Tsihlias, (unknown), George Deboer, Izabella Morava-Protzner, I Zbieranowski, Nandita Bhattacharya, (unknown), (unknown), J. Slingerland	280
12	UVB radiation induces p21Cip1/WAF1 and mediates G1 and S phase checkpoints. 1996 ·PubMed ·Teresa Petrocelli, Raymond Poon, (unknown), J. Slingerland, (unknown)	68
13	Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. 1995 ·PubMed ·Ling Liu, Norman J. Lassam, J. Slingerland, Denis Bailey, (unknown), Robert B. Jenkins, David Hogg	69
14	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. 1993 ·The EMBO Journal ·J. Slingerland, John R. Jenkins, Samuel Benchimol	96
15	Mutation of the p53 gene in human acute myelogenous leukemia 1991 ·Blood ·J. Slingerland, MD Minden, Samuel Benchimol	73
16	Mutation of the p53 gene in human acute myelogenous leukemia 1991 ·Blood ·J. Slingerland, MD Minden, Samuel Benchimol	111
17	Pulmonary manifestations of tuberous sclerosis in first degree relatives. 1989 ·Thorax ·J. Slingerland, Ronald F. Grossman, Dean Chamberlain, (unknown)	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact